Skip to main content

Table 1 Patient demographics and clinical parameters

From: Risk factors associated with cervical spine lesions in patients with rheumatoid arthritis: an observational study

Number of patients

185

Age (years) (IQR)

68 (62−74)

Sex (n) (male:female)

12:173

Age of RA onset (years) (IQR)

52 (43−64)

RA disease duration (years) (IQR)

11 (4.8−23)

CRP level (mg/dL) (IQR)

0.3 (0.1−1.1)

RF positive (n)

53 % (98/185)

MMP3 positive (n)

55 % (102/185)

DAS28-CRP (IQR)

2.3 (1.7−3.1)

RA stage (n)

I: 10, II: 46, III: 40, IV: 89

Prednisolone (n)

49 % (90/185)

MTX (n)

63 % (116/185)

Biological agents (n)

30 % (56/185)

BMD of the lumbar spine (YAM) (IQR)

82 % (71−93)

BMD of the femoral neck (YAM) (IQR)

66 % (58−66)

Previous joint surgery (n)

22 % (40/185)

Administered biological agents

 Abatacept

n = 17

 Etanercept

n = 12

 Infliximab

n = 10

 Tocilizumab

n = 8

 Certolizumab pegol

n = 5

 Adalimumab

n = 3

 Golimumab

n = 1

  1. BMD bone mineral density, CRP C-reactive protein, DAS28-CRP Disease Activity Score based on C-reactive protein, MTX methotrexate, MMP3 matrix metalloproteinase-3, RF rheumatoid factor, YAM young adult mean, IQR interquartile range